Two Japanese Pharmaceutical Firms See Profits, Two See Losses, In Cross-border Mergers
This article was originally published in PharmAsia News
Executive Summary
Japanese drug makers so far have faced mixed results in buying foreign counterparts to replace patent expirations for key drugs, particularly in the United States